解读信号调节蛋白α在固体瘤免疫治疗中的作用
Yulong Zhou1, Xiyang Tang1, Weiguang Du1
1Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Frontiers in immunology
|July 1, 2025
概括
信号调节蛋白α (SIRPα) 和它的配体CD47是癌症免疫治疗的关键标. 阻断这一轴可增强抗瘤反应,克服对当前治疗方法的抗性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 免疫检查点抑制剂 (ICI),如PD-1/PD-L1疗法,在癌症治疗中显示出有效性.
- 很大一部分患者对ICI没有反应,这凸显了癌症免疫疗法的未满足需求.
- 瘤免疫逃避机制复杂,需要新的治疗点.
研究的目的:
- 探索信号调节蛋白α (SIRPα) 作为癌症中一种创新的免疫调节点.
- 阐明SIRPα活性在不同细胞类型中的机制.
- 审查SIRPα向的癌症疗法及其潜力.
主要方法:
- 对SIRPα功能及其在癌症免疫力中的作用现有的文献的综述.
- 分析SIRPα与CD47的相互作用及其对髓状细胞功能的影响.
- 探索SIRPα在瘤生长和免疫逃避中的内在作用.
主要成果:
- 在髓状细胞表达的SIRPα通过CD47相互作用抑制了先天免疫力.
- 阻断SIRPα-CD47轴可以增强髓状细胞的抗瘤活性和适应性免疫力.
- 瘤内在的SIRPα可能会促进瘤进展和免疫逃生.
结论:
- 针对SIRPα-CD47通路提供了一个有前途的策略,以增强现有的癌症免疫疗法.
- 阻断SIRPα可以与治疗抗体和T细胞检查点抑制剂协同作用.
- 对瘤表达的SIRPα进行进一步的研究是有必要的,以开发新的治疗方法.
关键词:
CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47这就是SIRPα.免疫检查点抑制剂免疫检查点抑制剂免疫疗法 免疫疗法固体瘤是一个固体瘤.更多相关视频
12:24Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
Published on: September 29, 2016
7.1K
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
1.1K
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Tumor Immunotherapy
667
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
667
Interactions Between Signaling Pathways
6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
